← 返回

IL-23 信号传导不是小鼠非酒精性脂肪性肝炎模型中肝脏炎症和纤维化的重要驱动因素

英文原题:IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.

查看英文原题

IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.

PubMed 2022/09/15(内容时间) PLoS One Q2 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

非酒精性脂肪性肝病(NAFLD)是尚未满足的医疗需求,可进展为非酒精性脂肪性肝炎(NASH);若不干预,可能发展为肝硬化和肝细胞癌(HCC)。炎症是NASH的病理特征,靶向关键炎症介质可能带来治疗方法。

本研究旨在小鼠模型中探究IL-23信号对NASH进展的作用。研究显示,重组IL-23可促进肝脏中产生IL-17的细胞扩增,这些细胞主要为γδ T细胞和黏膜相关恒定T(MAIT)细胞。相应地,在西方饮食诱导的NASH模型中,IL-23信号是γδ T细胞和MAIT细胞扩增所必需的。

然而,在相同模型中,野生型小鼠与Il23r缺失小鼠的肝脏炎症及纤维化未见显著差异。此外,在胆碱缺乏、L-氨基酸定义并联合高脂饮食(CDA-HFD)诱导的NASH模型中,敲除Il23r也不影响肝脏炎症和纤维化。基于这些结果,作者提出IL-23信号并非临床前模型中NASH发病所必需,单独靶向该通路可能无法有效改善NASH患者的疾病进展。

展开英文摘要原文

Non-alcoholic fatty liver disease (NAFLD), represents an unmet medical need that can progress to non-alcoholic steatohepatitis (NASH), which, without intervention, can result in the development of cirrhosis and hepatocellular carcinoma (HCC). Inflammation is a pathological hallmark of NASH, and targeting key inflammatory mediators of NASH may lead to potential therapeutics for the disease.

Herein, we aimed to investigate the role of IL-23 signaling in NASH progression in murine models.

We showed that recombinant IL-23 can promote IL-17 producing cell expansion in the liver and that these cells are predominately γδ T cells and Mucosal Associated Invariant T cells (MAITs). Reciprocally, we found that IL-23 signaling is necessary for the expansion of γδ T cells and MAIT cells in the western diet (WD) diet induced NASH model.

However, we did not observe any significant differences in liver inflammation and fibrosis between wild type and Il23r-/- mice in the same NASH model.

Furthermore, we found that Il23r deletion does not impact liver inflammation and fibrosis in the choline-deficient, L-amino acid-defined and high-fat diet (CDA-HFD) induced NASH model. Based on these findings, we therefore propose that IL-23 signaling is not necessary for NASH pathogenesis in preclinical models and targeting this pathway alone may not be an effective therapeutic approach to ameliorate the disease progression in NASH patients.

论文信息

作者
Heredia JE、Sorenson C、Flanagan S、Nunez V、Jones C、Martzall A、Leong L、Martinez AP
单位
Department of Discovery Immunology, Genentech, South San Francisco, CA, United States of America.United States
期刊
PloS one2022
原文标识
PubMed 36107926 · DOI 10.1371/journal.pone.0274582